Comparative Pharmacology
Head-to-head clinical analysis: KEFTAB versus KEFZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFTAB versus KEFZOL.
KEFTAB vs KEFZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic